Targeted Oncology1h
FDA Grants Key Oncology Approvals and Designations in January 2025
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Hosted on MSN20d
Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer
The approval is backed by Amgen’s (AMGN) CodeBreaK 300 trial, in which patients on sotorasib 960 mg/panitumumab recorded over three months of median survival benefit without cancer progression ...
Nature1y
Trial shows the best way to treat colorectal cancer
The much-anticipated results of a trial of more than 800 participants in Japan revealed that, when coupled with standard chemotherapy, the drug panitumumab lowered the risk of death by 18% ...
ascopubs.org10d
Phase I/II study of cabozantinib alone or in combination with panitumumab in patients with MET-amplified metastatic colorectal cancer.
This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.
Pharmabiz17d
Amgen receives US FDA approval for Lumakras in combo with Vectibix for chemorefractory KRAS G12C-mutated metastatic colorectal cancer
Amgen receives US FDA approval for Lumakras in combo with Vectibix for chemorefractory KRAS G12C-mutated metastatic colorectal cancer: Thousand Oaks, California Monday, January 20 ...